节律性化疗在晚期肝细胞肝癌中的应用进展

Progress on metronomic chemotherapy for advanced hepatocellular carcinoma

原发性肝癌是我国常见的消化系统恶性肿瘤,其中以肝细胞肝癌(hepatocellular carcinoma,HCC)为最多见。多数HCC患者确诊时已为晚期,丧失了手术和局部治疗的机会,系统治疗被认为是晚期HCC的主要治疗方式。传统细胞毒类药物化疗对晚期HCC效果不明显,分子靶向药物索拉非尼虽有生存获益,但客观有效率仅为2%~3%,且价格昂贵。节律性化疗由于靶向肿瘤新生血管,在晚期转移性癌症中的治疗作用越来越受到关注。本文拟对节律性化疗在晚期HCC中的治疗进展做一简要综述。

Primary liver cancer, particularly hepatocellular carcinoma（HCC）, is a common type of digestive tumor in China. The majority of HCC patients is diagnosed with advanced stage and thus cannot be treated with surgery and local treatment. Systemic therapy is considered to be the main treatment of advanced HCC. The effect of traditional cytotoxic drug chemotherapy on advanced HCC is not evident. Although sorafenib, a molecular-targeted drug, has survival benefits, this drug is expensive and has low objective effective rate of only 2%-3%.Metronomic chemotherapy has received increasing attention because it targets tumor angiogenesis for the treatment of advanced metastatic cancer. This article aimed to review the progress of metronomic chemotherapy in advanced HCC treatment.